Current prescription trends in antibiotic prophylaxis: a multinational survey in esthetic plastic surgery

当前抗生素预防性用药处方趋势:一项针对美容整形外科的多国调查

阅读:1

Abstract

BACKGROUND: Surgical site infections pose a significant challenge in esthetic surgery, representing one of the most prevalent complications. While research in plastic surgery remains limited, reported rates of SSI range from 0.5% to 32.6%. Although the overall incidence of infections in most esthetic surgeries is low, it carries a significant burden of morbidity, hospital readmissions, and prolonged hospital stays. PURPOSE: Our study aims to provide evidence-based recommendations regarding the prescription of prophylactic antibiotics for the most common esthetic plastic surgery procedures, based on current trends among plastic surgeons. METHODS: An anonymous online survey was conducted among board-certified plastic surgeons to assess antibiotic prophylaxis practices. The survey was distributed via individual links on social media, plastic surgery society platforms, and private surgeon groups. Responses were recorded between February and April 2022 and were available in three different languages: English, Portuguese, and Spanish. The questionnaire covered eight common esthetic procedures, evaluating antibiotic use (prophylactic and non-prophylactic), duration, and type prescribed. RESULTS: Our study analyzed data from 2216 plastic surgery procedures, with 277 respondents answering each of the three questions per procedure. Cephalosporins were the most commonly prescribed antibiotics (73.3%), followed by quinolones (12.9%). Antibiotic therapy exceeded 5 days in 39.6% of cases, while 32.3% reported a 5-day duration. Single-dose prophylaxis was used in only 12% of cases. CONCLUSION: The rise of multidrug-resistant microorganisms is a growing global concern. Despite established guidelines on antibiotic prophylaxis, misuse among surgeons persists. Our findings highlight the urgent need for stricter antimicrobial stewardship, ensuring that antibiotics are prescribed only when clinically indicated. LEVEL OF EVIDENCE: III. Type of Study: Cross-Sectional, Observational Survey Study.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。